Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial.

Bouchi R, Nakano Y, Fukuda T, Takeuchi T, Murakami M, Minami I, Izumiyama H, Hashimoto K, Yoshimoto T, Ogawa Y

Endocrine journal3 Dec 2016Cited by 93 (Europe PMC)

PMID27916783DOI10.1507/endocrj.ej16-0449PepBankPUB-27916783

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In insulin-treated adults with type 2 diabetes, liraglutide plus insulin significantly reduced visceral fat area at 24 weeks versus insulin alone.
In plain wordsIn insulin-treated people with type 2 diabetes, adding liraglutide reduced belly fat at 24 weeks compared with insulin alone.
Peptide
Liraglutide
Outcome
DecreaseVisceral fat area (VFA) at 24 weeks
Study
n = 17
Comparator
Insulin alone (control group)
Analysis
Primary
Outcome group
Body composition · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide treatment significantly reduced VFA at 24 weeks; whereas, SFA was unchanged.
2 context sentences(design, population, supporting numbers)
Summary · context
Type 2 diabetic patients with insulin treatment were enrolled in this randomized, open-label, comparative study.
Summary · context
Participants were randomly assigned to liraglutide plus insulin (liraglutide group) and insulin treatment (control group) at 1:1 allocation.
Report a problemFND-2791678301
02HumanRandomized controlled trialEfficacy outcome
In insulin-treated adults with type 2 diabetes, subcutaneous fat area was unchanged with liraglutide.
In plain wordsIn insulin-treated people with type 2 diabetes, liraglutide did not change the fat under the skin.
Peptide
Liraglutide
Outcome
No significant changeSubcutaneous fat area (SFA)
Study
n = 17
Comparator
Insulin alone (control group)
Outcome group
Body composition · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide treatment significantly reduced VFA at 24 weeks; whereas, SFA was unchanged.
2 context sentences(design, population, supporting numbers)
Summary · context
Type 2 diabetic patients with insulin treatment were enrolled in this randomized, open-label, comparative study.
Summary · context
Participants were randomly assigned to liraglutide plus insulin (liraglutide group) and insulin treatment (control group) at 1:1 allocation.
Report a problemFND-2791678302
03HumanRandomized controlled trialEfficacy outcome
In insulin-treated adults with type 2 diabetes, liraglutide significantly reduced the urinary albumin-to-creatinine ratio at 24 weeks.
In plain wordsIn insulin-treated people with type 2 diabetes, liraglutide lowered albumin in the urine compared with insulin alone.
Peptide
Liraglutide
Outcome
DecreaseUrinary albumin-to-creatinine ratio (ACR)
Study
n = 17
Comparator
Insulin alone (control group)
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
ACR, LAI, and CRP levels were significantly reduced by liraglutide at 24 weeks and there was no difference in SMI between the two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Type 2 diabetic patients with insulin treatment were enrolled in this randomized, open-label, comparative study.
Summary · context
Participants were randomly assigned to liraglutide plus insulin (liraglutide group) and insulin treatment (control group) at 1:1 allocation.
Report a problemFND-2791678303
04HumanRandomized controlled trialEfficacy outcome
In insulin-treated adults with type 2 diabetes, liraglutide significantly reduced the liver attenuation index at 24 weeks.
In plain wordsIn insulin-treated people with type 2 diabetes, liraglutide lowered the liver attenuation index, a CT measure, at 24 weeks compared with insulin alone.
Peptide
Liraglutide
Outcome
DecreaseLiver attenuation index (LAI)
Study
n = 17
Comparator
Insulin alone (control group)
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
ACR, LAI, and CRP levels were significantly reduced by liraglutide at 24 weeks and there was no difference in SMI between the two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Type 2 diabetic patients with insulin treatment were enrolled in this randomized, open-label, comparative study.
Summary · context
Participants were randomly assigned to liraglutide plus insulin (liraglutide group) and insulin treatment (control group) at 1:1 allocation.
Report a problemFND-2791678304
05HumanRandomized controlled trialEfficacy outcome
In insulin-treated adults with type 2 diabetes, liraglutide significantly reduced C-reactive protein at 24 weeks.
In plain wordsIn insulin-treated people with type 2 diabetes, liraglutide lowered a blood inflammation marker compared with insulin alone.
Peptide
Liraglutide
Outcome
DecreaseC-reactive protein (CRP)
Study
n = 17
Comparator
Insulin alone (control group)
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
ACR, LAI, and CRP levels were significantly reduced by liraglutide at 24 weeks and there was no difference in SMI between the two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Type 2 diabetic patients with insulin treatment were enrolled in this randomized, open-label, comparative study.
Summary · context
Participants were randomly assigned to liraglutide plus insulin (liraglutide group) and insulin treatment (control group) at 1:1 allocation.
Report a problemFND-2791678305
06HumanRandomized controlled trialEfficacy outcome
In insulin-treated adults with type 2 diabetes, skeletal muscle index did not differ between the liraglutide and control groups.
In plain wordsIn insulin-treated people with type 2 diabetes, muscle mass measures did not differ between the liraglutide and insulin-only groups.
Peptide
Liraglutide
Outcome
No significant changeSkeletal muscle index (SMI)
Study
n = 17
Comparator
Insulin alone (control group)
Outcome group
Body composition · Musculoskeletal
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
ACR, LAI, and CRP levels were significantly reduced by liraglutide at 24 weeks and there was no difference in SMI between the two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Type 2 diabetic patients with insulin treatment were enrolled in this randomized, open-label, comparative study.
Summary · context
Participants were randomly assigned to liraglutide plus insulin (liraglutide group) and insulin treatment (control group) at 1:1 allocation.
Report a problemFND-2791678306
07HumanRandomized controlled trialOther
In insulin-treated adults with type 2 diabetes, changes in visceral fat area from baseline to 24 weeks were significantly associated with changes in LAI, albuminuria and HbA1c.
In plain wordsIn insulin-treated people with type 2 diabetes, changes in belly fat were linked to changes in liver fat, urine albumin and HbA1c.
Peptide
Liraglutide
Outcome
Not applicableAssociation of VFA change with LAI, albuminuria and HbA1c changes
Study
n = 17
Outcome group
Body composition · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Changes in VFA from baseline to 24 weeks were significantly associated with those in LAI, albuminuria, and HbA1c.
2 context sentences(design, population, supporting numbers)
Summary · context
Type 2 diabetic patients with insulin treatment were enrolled in this randomized, open-label, comparative study.
Summary · context
Participants were randomly assigned to liraglutide plus insulin (liraglutide group) and insulin treatment (control group) at 1:1 allocation.
Report a problemFND-2791678307
08HumanRandomized controlled trialEfficacy outcome
In insulin-treated adults with type 2 diabetes, liraglutide significantly improved quality of life scores for anxiety, dissatisfaction with treatment and satisfaction with treatment.
In plain wordsIn insulin-treated people with type 2 diabetes, liraglutide improved quality of life scores about anxiety and treatment satisfaction.
Peptide
Liraglutide
Outcome
IncreaseDiabetes treatment quality of life scores
Study
n = 17
Comparator
Insulin alone (control group)
Outcome group
Quality of life · Whole body
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide treatment significantly improved QOL scores associated with anxiety and dissatisfaction with treatment and satisfaction with treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Type 2 diabetic patients with insulin treatment were enrolled in this randomized, open-label, comparative study.
Summary · context
Participants were randomly assigned to liraglutide plus insulin (liraglutide group) and insulin treatment (control group) at 1:1 allocation.
Report a problemFND-2791678308
09HumanRandomized controlled trialSafety outcome
In insulin-treated adults with type 2 diabetes, no severe adverse events were observed in either group.
In plain wordsIn insulin-treated people with type 2 diabetes, no severe side effects were seen in either group.
Peptide
Liraglutide
Outcome
No significant changeSevere adverse events
Study
n = 17
Comparator
Insulin alone (control group)
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
No severe adverse events were observed in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Type 2 diabetic patients with insulin treatment were enrolled in this randomized, open-label, comparative study.
Summary · context
Participants were randomly assigned to liraglutide plus insulin (liraglutide group) and insulin treatment (control group) at 1:1 allocation.
Report a problemFND-2791678309

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT03590626

Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Medanta, The Medicity, Indian = 601 Jan 2019 to 18 Feb 2020

Non Alcoholic Fatty Liver Disease · Type2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 20 Feb 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.